CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

This study tests a CAR-T cell therapy that targets two proteins on cancer cells — CD19 and CD22 — in adults with relapsed or refractory B-cell leukemia (B-ALL) or B-cell lymphoma (B-NHL). CAR-T therapy involves engineering a patient's own immune cells to find and attack cancer cells. **You may be eligible if...** - You are 18 or older with confirmed B-cell leukemia or B-cell lymphoma that has returned or stopped responding to treatment - Your cancer has relapsed after multiple prior treatment lines, failed to respond, or relapsed after a stem cell transplant - You have good organ function and an ECOG performance status of 0–2 - Your estimated survival is at least 12 weeks **You may NOT be eligible if...** - You have received certain prior therapies such as bendamustine or fludarabine, or recent anti-T-cell antibodies - You have active or latent hepatitis B, active hepatitis C, or any uncontrolled infection - You have significant heart, liver, kidney, or brain conditions - You have an active autoimmune disease affecting major organs Talk to your doctor to see if this trial is right for you.